Artiva Biotherapeutics specializes in advancing a novel NK cell therapy platform targeting autoimmune diseases. The company's approach utilizes unengineered NK cells derived from cord blood ...
CAR-T Cells: As the largest class in adoptive cell therapy, CAR-T cells are being engineered for greater precision, reduced toxicity, and durable anti-tumor responses. Advancements aim to address ...
Artiva Biotherapeutics specializes in advancing a novel NK cell therapy platform targeting autoimmune diseases. The company's approach utilizes unengineered NK cells derived from cord blood, combined ...